Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
SAN FRANCISCO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that the Company has been selected by the People's Bank of China (PBOC) and Anhui Province government to participate in the Anhui SME Cross-border Investment and Trade Cooperation Conference (CITCC) being held on December 9-10, 2015, in Hefei City Anhui Province, China.
During this time, Amarantus executives will participate in high-level meetings with key officials, investors and potential strategic partners from China, focusing on global expansion opportunities for the Company’s therapeutics pipeline, specifically its Engineered Skin Substitute (ESS) program as a treatment for severe burns, as well as applications for its proprietary Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF).
Hosted by the PBOC and Anhui Province government, the conference provides a prominent platform to connect SMEs from the world’s largest economies to build cross-border partnerships and explore the possibilities of future joint ventures. Over 800 high-profile participants from the public and private sectors, including government officials, CEOs and top executives, will gather to discuss current local market trends of their respective industry and spark strategic ideas on future development through exclusive information exchanges. The event also features a distinguished panel of prominent figures, speaking about important SME development related issues.
“In light of the recent tragedies in Shangdong and Tianjin where explosions killed and severely injured hundreds of people, there is a pressing need for a game-changing wound care product such as ESS in China where growth and expansion will undoubtedly be coupled with construction and manufacturing-related accidents that will likely continue to have a devastating impact,” said Gerald E. Commissiong, President & CEO of Amarantus.
About the Anhui SME Cross-border Investment and Trade Cooperation Conference
The Small and Medium-sized Enterprises (SME) Cross-border Investment and Trade Cooperation Conference (CITCC) provides a prominent stage for SMEs from the world’s largest economies to build cross-border partnerships by traveling to Hefei City where prospective partners meet and see for themselves the possibilities of a future joint venture. It echoes a measurable surge of Chinese investments outside of China in recent years, both in magnitude and diversity, and is also called for as cross-border dynamism between SMEs in and out of China is picking up steam. At the center of live interaction, SMEs will meet and establish long-lasting cooperation with potential Chinese partners, based on successful video pairing beforehand.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. AMBS also has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact: Ascendant Partners, LLC Fred Sommer 732-410-9810 email@example.com